摘要
Eptifibatide是一种新型的血小板糖蛋白IIb/IIIa受体拮抗剂。它通过抑制血小板聚集的最后共同途径 ,具有抗血小板作用强、起效快、不良反应少等优点。临床研究表明 ,该药对不稳定型心绞痛、非Q波型心肌梗死。
Eptifibatide,a PG Ⅱb/Ⅲa receptor antagonist,exhibits its antiplatelet action by inhibiting the final common pathway (PG Ⅱa/Ⅲa receptor) of platelet.It has the advantage of potent effect,rapid onset of action,and less side effects.Clinical study showed that it can improve the prognosis of patients with unstable angina,non Q wave myocardial infarction and patients before reception of percutaneous coronary intervention. [
出处
《中国新药杂志》
CAS
CSCD
2000年第12期820-823,共4页
Chinese Journal of New Drugs
关键词
EPTIFIBATIDE
不稳定心绞痛
心肌梗死
药理
platelet aggregation
platelet glycoprotein Ⅱb/Ⅲa receptor
eptifibatide
unstable angina
myocardial infarction
